RESEARCH PEPTIDE FUNDAMENTALS / MATRIX
Five Peptides, Five Very Different Evidence Bases
How BPC-157, CJC-1295, MOTS-c, PT-141, and tirzepatide differ in mechanism, evidence maturity, regulatory status, and the single caution that matters most for each.
The short version
This page lines up all five compounds on the dimensions that actually matter when deciding how much weight to give any research-peptide claim: what problem it is studied for, how it is mechanistically supposed to work, how mature and how human the evidence actually is, and what the single most important safety caution is. The headline finding across this desk is that "research peptide" is not one category. It spans a two-person intravenous safety pilot (BPC-157) all the way to a 9,871-participant safety meta-analysis stacked on multiple Phase 3 efficacy trials (tirzepatide). Only PT-141 and tirzepatide are FDA-approved drugs with a defined human indication; BPC-157, CJC-1295, and MOTS-c remain unapproved research chemicals. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | BPC-157 | CJC-1295 | MOTS-c | PT-141 | Tirzepatide |
|---|---|---|---|---|---|
| Problem it maps to | Tendon/ligament/gut injury, tissue repair | Growth-hormone axis, recovery, body composition | Metabolic regulation, exercise and aging | Sexual desire (HSDD) | Metabolic regulation, weight, type 2 diabetes |
| Mechanism | Proposed VEGFR2-driven angiogenesis; FAK-paxillin, GH-receptor sensitization | GHRH-receptor agonist; raises GH/IGF-1 | AMPK activation via folate-cycle inhibition; direct CK2 binding | MC4R/MC3R melanocortin-receptor agonist (central) | Dual GIP/GLP-1 receptor agonist |
| Deepest human evidence | 2-person IV safety pilot [1] | Small PK studies, n=11 to a few dozen [10][11][12] | 1 observational cohort, n=94 [14] | Two Phase 3 RCTs, n=1,267 [20] | Multiple Phase 3 RCTs, thousands of participants [23][26][27] |
| Regulatory status | Not approved; not eligible for 503A compounding | Not approved anywhere | Not approved anywhere | FDA-approved (HSDD, premenopausal women only) | FDA-approved (T2D, weight management, sleep apnea) |
| Most-reported effect (anecdotal) | Faster tendon/joint recovery | Deeper sleep | No verified anecdotal pattern | Increased sexual desire | Appetite suppression / "food noise" quieting |
| Biggest cited caution | Human data extremely thin; theoretical pro-angiogenic cancer concern [2][4] | Never approved; discontinued development program | No human efficacy trials exist [15] | Approved only in one narrow population [20][22] | Gallbladder/biliary disease signal [25] |
Problem it maps to
The five compounds split cleanly by the problem someone is usually trying to solve. BPC-157 and CJC-1295 both sit in the tissue-repair-and-recovery space, though through completely different mechanisms — vascular repair versus hormone-axis stimulation. MOTS-c is the metabolic and longevity entry, working through a cellular energy sensor rather than a hormone receptor. PT-141 is the outlier in subject matter — sexual desire, not tissue or metabolism — and the only compound here targeting the brain directly rather than a peripheral tissue. Tirzepatide is the metabolic and weight heavyweight, sharing the incretin-receptor space with an entire other class of drugs not covered on this desk. Despite the shared "research peptide" label, these are five genuinely different pharmacological stories.
Mechanism
BPC-157's proposed mechanism (VEGFR2-driven blood-vessel growth) [4] and CJC-1295's mechanism (GHRH-receptor stimulation of the pituitary) [11] both act through classical receptor-signaling pathways, but on completely different axes — vascular versus endocrine. MOTS-c is mechanistically the odd one out: it does not primarily work through a cell-surface receptor at all, but through direct modulation of an intracellular enzyme (AMPK activation, direct CK2 binding) [13][17]. PT-141 and tirzepatide both work through classical G-protein-coupled receptors — melanocortin receptors for PT-141 [19], GIP and GLP-1 receptors for tirzepatide — but PT-141 acts centrally in the brain while tirzepatide acts on pancreas, gut, and brain simultaneously.
Evidence maturity
This is where the five compounds diverge most sharply. Tirzepatide's evidence base includes multiple multi-thousand-participant Phase 3 trials plus a dedicated 9,871-participant safety meta-analysis [23][25][26][27] — the deepest evidence on this desk by a wide margin. PT-141 has two identical Phase 3 trials (1,267 women) plus a 52-week open-label extension and a mechanistic fMRI study [19][20][21] — real, if narrower, trial-grade evidence. CJC-1295 has genuine early-phase human pharmacology — repeated-dose studies with clear dose-response findings — but nothing beyond Phase 1-scale work [11][12]. MOTS-c has exactly one human study, and it is observational, measuring naturally occurring levels rather than testing a dose [14]. BPC-157 has the thinnest human record of all: a two-person safety pilot, and a 2025 review that says so explicitly [1][2]. Reading these five side by side is the fastest way to understand why "research peptide" tells almost nothing about evidence quality on its own.
Regulatory status
PT-141 and tirzepatide are both FDA-approved prescription medicines, but with very different scopes: PT-141 is approved for exactly one population and one indication — premenopausal women with HSDD [20][22] — while tirzepatide covers three separate approvals (type 2 diabetes, weight management, sleep apnea). BPC-157, CJC-1295, and MOTS-c are not approved anywhere and are sold only as research chemicals for laboratory use — in 2023 the FDA specifically placed BPC-157 in a category not eligible for pharmacy compounding, and CJC-1295 was flagged for immunogenicity concerns at a 2024 FDA compounding advisory committee. None of the three unapproved compounds has a defined, regulator-sanctioned human dose.
Key caution
Each compound carries a different defining risk. For BPC-157, it is the sheer thinness of human evidence combined with a theoretical cancer concern tied to its pro-angiogenic mechanism [2][4]. For CJC-1295, it is that the original long-acting development program was discontinued and no large human trial has ever run [11]. For MOTS-c, it is that literally no human efficacy trial exists — every performance or metabolic claim comes from mice [15]. For PT-141, it is the narrowness of its approval: it is easy to find it discussed for uses the FDA never evaluated [20][22]. For tirzepatide, the deepest evidence base also surfaces the clearest signal — a significantly elevated risk of gallbladder or biliary disease across pooled trials [25]. More evidence does not mean fewer risks; it means better-characterized ones.